A scheme to solve the seemingly intractable problem of creating a viable market for companies developing novel antimicrobials has got underway in the UK, with antibiotics from Pfizer Inc. and Shionogi & Co. Ltd. leading the charge.
The two firms have signed agreements with NHS England for an innovative payment model for reimbursement of their respective antibiotics,...